A combination therapy using Eli Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) demonstrated superior efficacy in treating patients with both psoriatic arthritis and obesity compared to Taltz alone, according to new Phase 3 trial results announced by the pharmaceutical company. The FRONTIER-2 study showed that patients receiving the dual therapy achieved significantly better outcomes across multiple measures, including joint symptoms, skin manifestations, and weight reduction at 52 weeks.
The randomized, double-blind trial enrolled 411 adults with active psoriatic arthritis and a body mass index of 30 or higher. Participants receiving Taltz plus Zepbound showed a 45% greater likelihood of achieving ACR50 response—a measure indicating at least 50% improvement in arthritis symptoms—compared to those receiving Taltz with placebo. Additionally, the combination therapy group achieved an average weight loss of 15.3% versus just 2.1% in the Taltz-alone group. Skin clearance rates, measured by PASI 100 scores, were also notably higher in the combination arm.
These findings address a critical unmet need in psoriatic arthritis management, where obesity is highly prevalent and associated with reduced treatment response and worse disease outcomes. Research indicates that more than 40% of psoriatic arthritis patients have obesity, which can exacerbate inflammation, complicate joint symptoms, and diminish the effectiveness of standard therapies. The dual mechanism of targeting both inflammatory pathways through the IL-17A inhibitor Taltz and metabolic dysfunction through the GLP-1/GIP receptor agonist Zepbound represents a novel approach to treating this complex patient population.
The safety profile of the combination therapy was generally consistent with the known adverse event profiles of both medications individually, with gastrointestinal side effects being the most common treatment-related events. Eli Lilly plans to submit these data to regulatory authorities for potential approval of this combination indication, which could expand treatment options for patients managing both conditions simultaneously and potentially improve long-term outcomes in this challenging-to-treat population.
